Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH; X-VeRT Investigators. Cappato R, et al. Among authors: talajic m. Eur Heart J. 2014 Dec 14;35(47):3346-55. doi: 10.1093/eurheartj/ehu367. Epub 2014 Sep 2. Eur Heart J. 2014. PMID: 25182247 Clinical Trial.
Ventricular fibrillation in the Wolff-Parkinson-White syndrome.
Montoya PT, Brugada P, Smeets J, Talajic M, Della Bella P, Lezaun R, vd Dool A, Wellens HJ, Bayés de Luna A, Oter R, et al. Montoya PT, et al. Among authors: talajic m. Eur Heart J. 1991 Feb;12(2):144-50. doi: 10.1093/oxfordjournals.eurheartj.a059860. Eur Heart J. 1991. PMID: 2044547
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Connolly SJ, et al. Among authors: talajic m. JAMA. 2006 Jan 11;295(2):165-71. doi: 10.1001/jama.295.2.165. JAMA. 2006. PMID: 16403928 Clinical Trial.
Rhythm control versus rate control for atrial fibrillation and heart failure.
Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Roy D, et al. Among authors: talajic m. N Engl J Med. 2008 Jun 19;358(25):2667-77. doi: 10.1056/NEJMoa0708789. N Engl J Med. 2008. PMID: 18565859 Free article. Clinical Trial.
Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF).
Palardy M, Ducharme A, Nattel S, Tardif JC, White M, Racine N, Tétreault K, Dabouz F, Talajic M, Roy D; CTAF Investigators. Palardy M, et al. Among authors: talajic m. Can J Cardiol. 2008 Sep;24(9):709-13. doi: 10.1016/s0828-282x(08)70670-6. Can J Cardiol. 2008. PMID: 18787722 Free PMC article. Clinical Trial.
317 results